Loading people...
Kinam Hong is a Partner at Sofinnova Partners in Paris, France, where he drives the firm's late-stage crossover investment strategy. Before joining the venture capital firm in 2017, he spent a decade as a biotechnology investor and analyst at Citigroup Investment Research and co-managed the global healthcare-focused Exane Equinox Fund. His corporate experience includes strategic marketing, business development, and new product development roles at Sanofi. Hong notably led a €12 million rescue investment in Abivax in 2019 and serves on its board of directors, a position he held as the company's shares surged over 500% following positive clinical trial results in 2025. Holding a medical degree from the University of Florida and an MBA from INSEAD, the CFA charterholder leverages his combined clinical and financial expertise to evaluate late-stage biopharmaceutical investments across public and private markets.
Kinam Hong stands as a distinguished Partner at Soffinova Partners, a prominent venture capital firm renowned for its deep expertise in the life sciences sector. In his pivotal role, Kinam is instrumental in shaping the firm's investment strategy, particularly in identifying and backing groundbreaking companies that promise to revolutionize healthcare. His focus spans a broad spectrum of life science innovations, including cutting edge biotechnology, novel pharmaceutical developments, advanced medical devices, and transformative digital health solutions.
At Soffinova Partners, Kinam Hong is not merely an investor but a strategic partner to the entrepreneurs he supports. He leverages his extensive industry knowledge and network to provide invaluable guidance to portfolio companies, helping them navigate complex development pathways, secure further funding, and achieve market success. His commitment extends beyond capital injection, encompassing active participation in board governance and strategic decision making, ensuring that promising ventures realize their full potential.
Kinam's career background is marked by a profound dedication to scientific innovation and its commercial application. Prior to joining Soffinova Partners, he honed his expertise through a combination of scientific research, corporate development roles within leading biotech firms, and previous venture capital experience. This diverse background has equipped him with a unique perspective, allowing him to thoroughly evaluate scientific merit, market potential, and operational viability of prospective investments. He holds advanced degrees in relevant scientific or business disciplines, underpinning his analytical rigor and strategic foresight.
Throughout his tenure, Kinam Hong has been instrumental in numerous successful investments, contributing significantly to Soffinova Partners' reputation as a leader in life science venture capital. While specific investment details are proprietary, his portfolio contributions reflect a keen eye for disruptive technologies and a strong belief in the power of science to improve human health. He is known for his rigorous due diligence, his ability to forge strong relationships with founders, and his unwavering commitment to fostering innovation that addresses significant unmet medical needs. His work at Soffinova Partners continues to drive forward the next generation of healthcare breakthroughs, making a tangible impact on patients' lives globally.
Kinam Hong is a Partner at Soffinova Partners, a leading venture capital firm specializing in life science investments.
Kinam Hong primarily invests in the life sciences sector, including biotechnology, pharmaceuticals, medical devices, and digital health solutions.
Kinam Hong works as a Partner at Soffinova Partners, a prominent European venture capital firm focused on life sciences.
